-
H.C. Wainwright Downgrades United Therapeutics To Neutral
Wednesday, June 15, 2016 - 12:04pm | 315Read More...H.C. Wainwright & Co. analysts Andrew Fein and Emile Yu have downgraded the shares of United Therapeutics Corporation (NASDAQ: UTHR) to a Neutral rating, pointing out that the scales are tipping the other way. The brokerage also lowered its price objective to $95. "We see no short-term drivers...
-
H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare
Tuesday, March 15, 2016 - 10:40am | 259Read More...On Tuesday, H.C. Wainwright & Co. issued a company note on Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) after the company had a positive Phase 3 trial win in oncology, with a survival win in AML of their drug Vyxeos. After the news, analysts at H.C. Wainwright reiterated their Buy rating...
